title: Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Research Group on Diffuse Pulmonary Diseases.
abstract: Idiopathic pulmonary fibrosis is defined as a chronic fibrosing interstitial pneumonia limited to the lung, of unknown cause, with poor prognosis and few treatment options. In recent years there has been an increase in their prevalence, probably due to the optimization of diagnostic methods and increased life expectancy. The ATS/ERS Consensus (2000) established the diagnostic criteria and recommendations for the assessment of the disease course and treatment. Later studies have helped to redefine diagnostic criteria and treatment options. In 2011, an international consensus was published, establishing diagnostic criteria and new treatment strategies. These guidelines have been updated with the newest aspects of diagnosis and treatment of idiopathic pulmonary fibrosis. A level of evidence has been identified for the most relevant questions, particularly with regard to treatment options.
authors.affiliation: Servicio de Neumología, Hospital Clínic, Barcelona, España. axaubet@clinic.ub.es
authors.forename: Antoni
authors.initials: A
authors.lastname: Xaubet
authors.forename: Julio
authors.initials: J
authors.lastname: Ancochea
authors.forename: Elena
authors.initials: E
authors.lastname: Bollo
authors.forename: Estrella
authors.initials: E
authors.lastname: Fernández-Fabrellas
authors.forename: Tomás
authors.initials: T
authors.lastname: Franquet
authors.forename: Maria
authors.initials: M
authors.lastname: Molina-Molina
authors.forename: Maria Angeles
authors.initials: MA
authors.lastname: Montero
authors.forename: Anna
authors.initials: A
authors.lastname: Serrano-Mollar
mesh_terms: D000111:Acetylcysteine / Q000627:therapeutic use; D001706:Biopsy; D001992:Bronchoalveolar Lavage Fluid; D064987:Cell- and Tissue-Based Therapy; D002986:Clinical Trials as Topic; D000075202:Contraindications; D003952:Diagnostic Imaging; D018450:Disease Progression; D019317:Evidence-Based Medicine; D005764:Gastroesophageal Reflux / Q000150:complications; D015316:Genetic Therapy; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology; D054990:Idiopathic Pulmonary Fibrosis / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D007155:Immunologic Factors / Q000627:therapeutic use; D015994:Incidence; D007211:Indoles / Q000627:therapeutic use; D008168:Lung / Q000473:pathology; D016040:Lung Transplantation; D010102:Oxygen Inhalation Therapy; D010166:Palliative Care; D015995:Prevalence; D011379:Prognosis; D011656:Pulmonary Emphysema / Q000209:etiology; D011728:Pyridones / Q000627:therapeutic use; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology
chemical_list: D005938:Glucocorticoids; D007155:Immunologic Factors; D007211:Indoles; D011728:Pyridones; C093844:pirfenidone; C530716:nintedanib; D000111:Acetylcysteine
keywords: Diagnosis; Diagnóstico; Fibrosis pulmonar idiopática; Idiopathic pulmonary fibrosis; Tratamiento; Treatment